These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 1939964)

  • 1. Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits.
    Sherry S; Marder VJ
    J Am Coll Cardiol; 1991 Nov; 18(6):1579-82. PubMed ID: 1939964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thrombolytic drugs in acute myocardial infarct].
    Ambrosioni E; Degli Esposti D
    Cardiologia; 1991 Dec; 36(12 Suppl 1):395-402. PubMed ID: 1841796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolysis: the need for a critical review.
    Monrad ES
    J Am Coll Cardiol; 1991 Nov; 18(6):1573-8. PubMed ID: 1939963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in thrombolytic therapy.
    Collen DC; Gold HK
    Thromb Res Suppl; 1990; 10():105-31. PubMed ID: 2180114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study.
    Bassand JP; Cassagnes J; Machecourt J; Lusson JR; Anguenot T; Wolf JE; Maublant J; Bertrand B; Schiele F
    Circulation; 1991 Sep; 84(3):1107-17. PubMed ID: 1909218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction.
    Sherry S; Marder VJ
    Ann Intern Med; 1991 Mar; 114(5):417-23. PubMed ID: 1899546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction.
    Held PH; Teo KK; Yusuf S
    Circulation; 1990 Nov; 82(5):1668-74. PubMed ID: 2146038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic therapy in acute myocardial infarction.
    Rutherford JD; Braunwald E
    Chest; 1990 Apr; 97(4 Suppl):136S-145S. PubMed ID: 2108851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous thrombolytic therapy in myocardial infarction: an analytical review.
    Shammas NW; Zeitler R; Fitzpatrick P
    Clin Cardiol; 1993 Apr; 16(4):283-92. PubMed ID: 8458108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
    Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
    Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO.
    Bates ER
    Chest; 1992 Apr; 101(4 Suppl):140S-150S. PubMed ID: 1555479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing thrombolytic agents: focus on safety and efficacy.
    Collen D
    Am J Cardiol; 1992 Jan; 69(2):71A-81A. PubMed ID: 1729881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival following thrombolytic therapy.
    Sleight P
    Eur Heart J; 1990 Aug; 11 Suppl F():1-4. PubMed ID: 2121486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic, antiplatelet, and antithrombotic agents.
    Grines CL
    Am J Cardiol; 1992 Dec; 70(21):18I-26I. PubMed ID: 1471601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.